Radiosensitivity and capacity for radiation-induced sublethal damage repair of canine transitional cell carcinoma (TCC) cell lines

Veterinary and Comparative Oncology

Volumn 9, Issue 3, 2011, Pages 232-240

  Parfitt, S L ^a   Milner, R J ^a   Salute, M E ^a   Hintenlang, D E ^a   Farese, J P ^a   Bacon, N J ^a   Bova, F J ^b   Rajon, D A ^b   Lurie, D M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ratio; Dogs; Radiation; Sublethal damage repair capacity; Surviving fraction at 2 Gy (SF 2); Transitional cell carcinoma

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; PATHOLOGY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; URINARY TRACT CANCER;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DOG DISEASES; DOGS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; RADIATION TOLERANCE; UROLOGIC NEOPLASMS;

CANIS FAMILIARIS;

EID: 80051798074     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00258.x     Document Type: Article

References (33)

1. Henry CJ. Management of transitional cell carcinoma. Veterinary Clinics of North America: Small Animal Practice 2003; 33: 597-613.
2. Knapp D, Glickman NW, DeNicola DB, Bonney PL, Lin TL and Glickman LT. Naturally-occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urologic Oncology 2000; 5: 47-59.
3. Mutsaers AJ, Widmer WR and Knapp DW. Canine transitional cell carcinoma. Journal of Veterinary Internal Medicine 2003; 17: 136-144.
4. Osborne CA, Low DG, Perman V and Barnes DM. Neoplasms of the canine and feline urinary bladder: incidence, etiologic factors, occurrence and pathologic features. American Journal of Veterinary Research 1968; 29: 2041-2055.
5. Strafuss AC and Dean MJ. Neoplasms of the canine urinary bladder. Journal of the American Veterinary Medical Association 1975; 166: 1161-1163.
6. Valli VE, Norris A, Jacobs RM, Laing E, Withrow S, Macy D, Tomlinson J, McCaw D, Ogilvie GK, Pidgeon G and Henderson RA. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. Journal of Comparative Pathology 1995; 113: 113-130.
7. Michaelson MD, Shipley WU, Heney NM, Zietman AL and Kaufman DS. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. British Journal of Cancer 2004; 90: 578-581.
8. th edn., V DeVita, S Hellman and S Rosenberg, eds., Philadelphia, PA, Lippincott, Williams, & Wilkins, 2005: 1168-1192.
9. Poirier VJ, Forrest LJ, Adams WM and Vail DM. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study. Journal of the American Animal Hospital Association 2004; 40: 131-136.
10. Walker M and Breider M. Intraoperative radiotherapy of canine bladder cancer. Veterinary Radiology and Ultrasound 1987; 28: 200-204.
11. Withrow SJ, Gillette EL, Hoopes PJ and McChesney SL. Intraoperative irradiation of 16 spontaneously occurring canine neoplasms. Veterinary Surgery 1989; 18: 7-11.
12. Hill R and Bristow R. The scientific basis of radiotherapy. In: The Basic Science of Oncology, 4th edn., I Tannock, R Hill, R Bristow and L Harrington, eds., New York, NY, McGraw-Hill, 2005.
13. Fertil B and Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. International Journal of Radiation Oncology, Biology, Physics 1985; 11: 1699-1707.
14. Fertil B and Malaise EP. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. International Journal of Radiation Oncology, Biology, Physics 1981; 7: 621-629.
15. Fitzpatrick CL, Farese JP, Milner RJ, Salute ME, Rajon DA, Morris CG, Bova FJ, Lurie DM and Siemann DW. Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines. American Journal of Veterinary Research 2008; 69: 1197-1202.
16. th edn. Philadelphia, PA, Lippincott Williams & Wilkins, 2006.
17. th edn., I Tannock, R Hill, R Bristow and L Harrington, eds., New York, NY, McGraw-Hill, 2005: 261-286.
18. Deacon J, Peckham MJ and Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiotherapy and Oncology 1984; 2: 317-323.
19. Williams MV, Denekamp J and Fowler JF. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. International Journal of Radiation Oncology, Biology, Physics 1985; 11: 87-96.
20. Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R and Knapp DW. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urologic Oncology 2009; 27: 284-292.
21. Munshi A, Hobbs M and Meyn RE. Clonogenic cell survival assay. Methods in Molecular Medicine 2005; 110: 21-28.
22. Banasiak D, Barnetson AR, Odell RA, Mameghan H and Russell PJ. Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiation Oncology Investigations 1999; 7: 77-85.
23. Barnetson AR, Banasiak D, Fisher RJ, Mameghan H, Ribeiro JC, Brown K, Brown JL, O'Mara SM and Russell PJ. Heterogeneity of in vitro radiosensitivity in human bladder cancer cells. Radiation Oncology Investigations 1999; 7: 66-76.
24. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clinical Oncology (Royal College of Radiologists (Great Britian)) 2007; 19: 289-301.
25. Pos FJ, Hart G, Schneider C and Sminia P. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? International Journal of Radiation Oncology, Biology, Physics 2006; 64: 1168-1173.
26. Farese JP, Milner R, Thompson MS, Lester N, Cooke K, Fox L, Hester J and Bova FJ. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. Journal of the American Veterinary Medical Association 2004; 225: 1567-1572, 48.
27. th edn., WS Dernell, NP Ehrhart, RC Straw and DM Vail, eds., St. Louis, MO, Saunders, 2007.
28. Koukourakis MI, Tsolos C and Touloupidis S. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer. Urology 2007; 69: 245-250.
29. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, Fossâ SD, Uscinska BM and Parmar MK. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. International Journal of Radiation Oncology, Biology, Physics 2000; 47: 379-388.
30. Arthur JJ, Kleiter MM, Thrall DE and Pruitt AF. Characterization of normal tissue complications in 51 dogs undergoing definitive pelvic region irradiation. Veterinary Radiology and Ultrasound 2008; 49: 85-89.
31. Anderson CR, McNiel EA, Gillette EL, Powers BE and LaRue SM. Late complications of pelvic irradiation in 16 dogs. Veterinary Radiology and Ultrasound 2002; 43: 187-192.
32. DeLuca AM, Johnstone PA, Ollayos CW, Bacher JD, Terrill RE, Kinsella TJ and Sindelar WF. Tolerance of the bladder to intraoperative radiation in a canine model: a five-year follow-up. International Journal of Radiation Oncology, Biology, Physics 1994; 30: 339-345.
33. Kinsella TJ, Sindelar WF, DeLuca AM, Barnes M, Tochner Z, Mixon A and Glatstein E. Tolerance of the canine bladder to intraoperative radiation therapy: an experimental study. International Journal of Radiation Oncology, Biology, Physics 1988; 14: 939-946.